Subject(s)
Pain/etiology , Scrotum , Spermatocele/complications , Spermatocele/diagnosis , Acute Disease , Adult , Humans , Male , Spermatocele/surgeryABSTRACT
Deregulated proliferation is one of the fundamental characteristics of carcinogenesis. p27 is one of the most well characterized negative cell cycle regulator. In our previous study, expression of p27 protein was found to be dramatically suppressed on stimulation of cell proliferation by calculi in the rodent urinary bladder, withdrawal of the insult resulting in re-expression of p27 and regression of urothelial hyperplastic lesions. In the present study, to evaluate how loss of function impacts on urinary bladder carcinogenesis, N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN), a bladder carcinogen was given to p27 knockout mice. Males and females with either null, hetero or wild-type p27 alleles were divided into 2 groups, one given drinking water containing 0.05% BBN for 10 weeks and the other receiving distilled water, then, killed at week 20. The experiment was repeated for confirmation of the outcome. In the second experiment, performed with a larger number of animals, the incidence of urinary bladder carcinomas was significantly higher in female p27-null mice than in their wild-type counterparts. p27 deficiency also resulted in their increase of relative weights of urinary bladders and section areas of carcinomas in BBN-treated mice. Interestingly, while BrdU labeling indices generally increased with progression of mucosal proliferative lesions, from normal epithelium, through hyperplasia to carcinoma, there was no significant variation with the p27 genotype, in tumors as well as normal urothelium. These findings suggest that p27 deficient mice have elevated susceptibility to BBN-induction of urinary bladder carcinogenesis through a mechanism which might be independent of acceleration of cell cycling.
Subject(s)
Butylhydroxybutylnitrosamine/toxicity , Carcinogens/toxicity , Cell Proliferation/drug effects , Cyclin-Dependent Kinase Inhibitor p27/physiology , Urinary Bladder Neoplasms/chemically induced , Animals , Base Sequence , Body Weight/drug effects , Cyclin-Dependent Kinase Inhibitor p27/genetics , DNA Primers , Female , Immunohistochemistry , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Organ Size/drug effects , Urinary Bladder Neoplasms/pathologyABSTRACT
A subcutaneous mass in the perineum of a middle-aged man was excised and pathologically diagnosed at first as 'undifferentiated carcinoma' of unknown origin, which recurred 2 years later without any metastasis. Further histological evaluation ultimately established a correct diagnosis of 'proximal-type epithelioid sarcoma', a variant of rare epithelioid sarcoma. This type of tumor may confuse pathologists because its histological characteristics resemble undifferentiated carcinoma or malignant rhabdoid tumor. Frequent immunoreactivity of CD34, in addition to expression of keratins, epithelial membrane antigen and vimentin, provides strong support for the diagnosis of this rare neoplasm. Urologists should be aware that this sarcoma commonly occurs in the genital regions.
Subject(s)
Genital Neoplasms, Male/diagnosis , Perineum , Sarcoma/diagnosis , Biomarkers, Tumor/metabolism , Combined Modality Therapy , Diagnosis, Differential , Follow-Up Studies , Genital Neoplasms, Male/metabolism , Genital Neoplasms, Male/therapy , Humans , Keratins/metabolism , Magnetic Resonance Imaging , Male , Middle Aged , Sarcoma/metabolism , Sarcoma/therapy , Tomography, X-Ray Computed , Vimentin/metabolismABSTRACT
BACKGROUND: Our previous study clearly demonstrated that decreased expression of prothymosin alpha (PTMA) was associated with inhibition of rat prostate carcinogenesis by isoflavones. The purpose of the present investigation was to provide a better understanding of the role of PTMA in human prostate cancers. METHODS AND RESULTS: PTMA expression in 68 prostate cancer cases and in prostate cancer cell lines was examined by immunohistochemistry and immunoblotting, and its levels were increased with progression from normal epithelium, through prostatic intraepithelial neoplasia (PIN) to carcinomas, correlating with the Gleason's pattern. All cell lines studied (LNCaP, 22Rv1, DU145, and PC3) showed high PTMA expression compared with prostate epithelial cells (PrEC). Knockdown of PTMA expression in PC3 cells by RNAi resulted in the inhibition of both cell growth and invasion in vitro. CONCLUSIONS: The present study clearly demonstrated that PTMA expression is intimately involved in the differentiation and progression of human prostate cancers, and could be a target for therapy and diagnostic purposes.
Subject(s)
Prostatic Neoplasms/genetics , Protein Precursors/genetics , Thymosin/analogs & derivatives , Autopsy , Cell Division , Cell Line, Tumor , DNA Primers , Disease Progression , Gene Deletion , Humans , Immunohistochemistry , Male , Neoplasm Staging , Neoplasms, Glandular and Epithelial/genetics , Neoplasms, Glandular and Epithelial/pathology , Prostatic Hyperplasia/pathology , Prostatic Neoplasms/pathology , Reverse Transcriptase Polymerase Chain Reaction , Thymosin/geneticsABSTRACT
OBJECTIVES: To evaluate prophylactic effects of bisphosphonate (BP) on skeletal lesions induced by prostate cancer (CaP). METHODS: Incadronate, a third-generation BP, was administered weekly for 4 weeks, with or without 4-week pre-administration, to rats whose calvaria had been inoculated with syngeneic CaP tissue. RESULTS: The transplanted CaP grew up and caused bone resorption with osteoblastic changes regardless of incadronate treatment. Although decrease in bone resorption accompanied by reduced number of osteoclasts was shown by incadronate administration, pre-administration had no additional inhibitory effect on bone destruction and Ki-67 labeling indices of CaP cells were not altered. CONCLUSIONS: These results indicate that application of BP alone is not sufficient to prevent skeletal lesions due to CaP in patients with high risk of bone metastases although it is useful in inhibition of cancer-induced bone resorption with osteoblastic changes.
Subject(s)
Bone Density Conservation Agents/therapeutic use , Bone Neoplasms/prevention & control , Bone Neoplasms/secondary , Diphosphonates/therapeutic use , Prostatic Neoplasms/pathology , Animals , Male , Neoplasm Transplantation , Rats , Rats, Inbred F344 , Treatment FailureABSTRACT
We developed a rodent model that mimics the osteoblastic and osteolytic changes associated with human metastatic prostate cancer. Microarray analysis identified MMP-7, cathepsin-K, and apolipoprotein D as being upregulated at the tumor-bone interface. MMP-7, which was produced by osteoclasts at the tumor-bone interface, was capable of processing RANKL to a soluble form that promoted osteoclast activation. MMP-7-deficient mice demonstrated reduced prostate tumor-induced osteolysis and RANKL processing. This study suggests that inhibition of MMP-7 will have therapeutic benefit in the treatment of prostate cancer-induced osteolysis.
Subject(s)
Carrier Proteins/metabolism , Matrix Metalloproteinase 7/metabolism , Membrane Glycoproteins/metabolism , Osteolysis/pathology , Prostatic Neoplasms/metabolism , Acid Phosphatase/metabolism , Actins/metabolism , Animals , Carrier Proteins/genetics , Carrier Proteins/pharmacology , Disease Models, Animal , Down-Regulation/genetics , Gene Expression/genetics , Gene Expression Profiling , Glycoproteins/genetics , Humans , Isoenzymes/metabolism , Male , Matrix Metalloproteinase 7/genetics , Membrane Glycoproteins/genetics , Membrane Glycoproteins/pharmacology , Mice , Mice, Inbred C57BL , Mice, Knockout , Models, Biological , Monocytes/drug effects , Monocytes/metabolism , Osteoclasts/metabolism , Osteoclasts/pathology , Osteolysis/etiology , Osteolysis/metabolism , Osteoprotegerin , Parathyroid Hormone-Related Protein/genetics , Prostatic Neoplasms/complications , RANK Ligand , Rats , Rats, Inbred F344 , Receptor Activator of Nuclear Factor-kappa B , Receptors, Cytoplasmic and Nuclear/genetics , Receptors, Tumor Necrosis Factor/genetics , Skull/pathology , Tartrate-Resistant Acid Phosphatase , Up-Regulation/geneticsABSTRACT
Intake of isoflavones derived from soybean products may impact on prostate cancer risk. Here we evaluated the effects of Fujiflavone, a commercial isoflavone supplement, on rat prostate carcinogenesis induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), the most abundant heterocyclic amine in cooked meat. F344 male rats were given intragastric administrations of PhIP at the dose of 200 mg/kg twice weekly for 10 weeks. The rats subsequently fed a diet containing 0.25% Fujiflavone showed a significantly lower incidence of prostate carcinomas than those fed a soy-free diet. Interestingly fewer carcinomas but more foci of prostatic intra-epithelial neoplasia (PIN) were observed in the Fujiflavone group although the sum of the two lesions was not altered by Fujiflavone treatment. cDNA array analyses confirmed by semi-quantitative reverse transcription polymerase chain reactions (RT-PCR) revealed Fujiflavone to alter gene expression of ornithine decarboxylase (ODC), prothymosin alpha (PTA) in the rat prostate. No modification of PhIP-induced colon carcinogenesis was evident, except for increased multiplicity of aberrant crypt foci >4 crypts in size. These results indicate that a commercial isoflavone supplement can inhibit PhIP-induced rat prostate carcinogenesis without any adverse effects, possibly by inhibiting progression of PIN to carcinoma, and that down-regulation of ODC and PTA could be related to the underlying mechanisms. Thus, intake of dietary isoflavones can be promising for prevention of human prostate cancer.
